Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2012. The report details a specific share repurchase transaction executed on March 9, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 400,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,423.5 pence per share; lowest price paid was 1,408.5 pence per share.
- Treasury Holdings (Settled): 511,197,927 shares (9.20% of total issued share capital).
- Treasury Holdings (Including Unsettled): 512,597,927 shares (10.16% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,046,093,449 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 400,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.16% when including unsettled purchases. The filing does not provide comparative data against prior periods for these specific metrics.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules. The text explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (511,197,927 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.20% Treasury ownership calculation.
- Check the status of the 1,400,000 shares mentioned as "purchased but not yet settled" to confirm final settlement dates.
- Review the original shareholder authorization from the May 5, 2011 AGM to ensure the repurchase volume remains within approved limits.